Logo image
Sign in
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Journal article

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group

Bradley J. Monk, Michael W. Sill, Parviz Hanjani, Robert Edwards, Jacob Rotmensch, Koen De Geest, Albert J. Bonebrake and Joan L. Walker
Gynecologic Oncology, Vol.120(3), pp.459-463
2011
PMID: 21144560

Metrics

4 Record Views

Details